• PDF / 141,732 Bytes
• 1 Pages / 595.245 x 841.846 pts (A4) Page_size
• 95 Downloads / 150 Views

DOWNLOAD

REPORT

---

1

S

Neuroleptic malignant syndrome: case report A 28-year-old man developed neuroleptic malignant syndrome following treatment with thioridazine and valproate [therapeutic indications not clearly stated]. The man, who had a history of bipolar mood disorder and mental retardation, was hospitalised with muscle rigidity, impaired consciousness, elevated body temperature, cognitive impairment and diaphoresis [time to reaction onset not stated]. He was receiving thioridazine and valproate, which had been administered for 6 months [routes and dosages not stated]. He exhibited postures characteristic of catatonia and was mute. Tests revealed the following values: temperature 38.2°C, creatine kinase 1245 U/L, BP 131/82mm Hg, HR 114 beats/min and respiratory rate 18; other laboratory results including electrolytes were also raised. He was living in a mental disorder institute following several previous psychiatric admissions. Antipsychotic drugs were withdrawn; the man was diagnosed with neuroleptic malignant syndrome. He developed worsening muscle rigidity and catatonia, and electroconvulsive therapy was performed under anaesthesia. After a few weeks of treatment, decreasing creatine kinase levels were noted with improved psychotic symptoms; he returned home with no additional complications. Author comment: "[T]he patient met three major (rigidity, hyperthermia, rising of CK) and three minor criteria(tachycardia, diaphoresis, cognitive impairment) of NMS." Arasteh M, et al. Propofol-remifentanil combination for management of electroconvulsive therapy in a patient with neuroleptic malignant syndrome. Case Reports in Medicine 2012: No. 585713, Jan 2012. Available from: URL: http:// 803074597 dx.doi.org/10.1155/2012/585713 - Iran

0114-9954/10/1413-0001/$14.95 Adis © 2010 Springer International Publishing AG. All rights reserved

Reactions 4 Aug 2012 No. 1413